Oncology drug development: pipeline, trials and approval odds
Cancer drug development, from lung and breast cancer to pancreatic, colorectal, and endometrial cancer: active industry trials, historical approval odds, and the experimental and newly approved drugs we track.
Key points
- Oncology is by far the busiest area of drug development: lung and breast cancer alone account for hundreds of active industry Phase 3 trials on ClinicalTrials.gov.
- It has also been one of the hardest: in the BIO 2011–2020 analysis, only 5.3% of oncology programs entering Phase 1 reached approval, and oncology had the lowest Phase 3 success rate of the major areas.
- Once a cancer drug application reaches the FDA, however, approval has been likely: 92.0% historically, partly because expedited pathways are widely used for serious cancers.
- Precision approaches are paying off: in 2026 the FDA approved a broad RAS inhibitor (daraxonrasib) for pancreatic cancer and the first PROTAC protein degrader (vepdegestrant) for ESR1-mutated breast cancer.
- Overall survival still decides close calls: in November 2026 the FDA declined ivonescimab because its global trial improved progression-free but not overall survival with statistical significance.
Active industry trials
About 2,624 industry-sponsored Phase 1–3 trials in this area are active on ClinicalTrials.gov (recruiting, not yet recruiting, active, or enrolling by invitation), retrieved Nov 19, 2026. Counts come from condition searches; a trial listing several conditions can appear in more than one row.
| Condition | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|
| Lung cancer | 622 | 532 | 296 |
| Breast cancer | 349 | 263 | 184 |
| Colorectal cancer | 334 | 231 | 56 |
| Pancreatic cancer | 252 | 179 | 46 |
| Endometrial cancer | 118 | 79 | 23 |
| Whole area | 1056 | 970 | 598 |
Most active Phase 3 sponsors
- AstraZeneca (62 active Phase 3 trials)
- Merck Sharp & Dohme LLC (34 active Phase 3 trials)
- Sichuan Baili Pharmaceutical Co., Ltd. (22 active Phase 3 trials)
- Hoffmann-La Roche (20 active Phase 3 trials)
- Eli Lilly and Company (14 active Phase 3 trials)
- Pfizer (14 active Phase 3 trials)
- Jiangsu HengRui Medicine Co., Ltd. (14 active Phase 3 trials)
- Bristol-Myers Squibb (13 active Phase 3 trials)
Historical approval odds
Share of programs at each stage that went on to FDA approval, 2011–2020.
| Disease area (as defined by the source) | From Phase 1 | From Phase 2 | From Phase 3 | From submission |
|---|---|---|---|---|
| Oncology (n = 4,179) | 5.3% | 10.8% | 43.9% | 92% |
| All indications (n = 12,728) | 7.9% | 15.1% | 52.4% | 90.6% |
Source: BIO, Informa Pharma Intelligence, QLS Advisors (2021), likelihood-of-approval table (Figure 5b). The report does not publish which conditions it assigns to each disease area. It does note that oncology accounted for about a third of all phase transitions analyzed. These are averages for groups of programs, not predictions for any drug. See our methodology.
Tracked drugs in this area
Daraxonrasib (Rasonque)
Revolution Medicines · Small molecule (oral, once daily)
FDA-approved August 26, 2026 for previously treated metastatic pancreatic cancer after roughly doubling survival in Phase 3
FDA-approvedVepdegestrant (Veppanu)
Arvinas · PROTAC protein degrader (oral, once daily)
FDA-approved May 1, 2026 for ESR1-mutated breast cancer: the first approved PROTAC
Approved outside the U.S.Sacituzumab tirumotecan
Merck & Co. (MSD) · Antibody–drug conjugate (ADC)
Approved in China since 2024; under FDA priority review for previously treated endometrial cancer, decision date June 15, 2027 (company-reported)
Not yet approvedZanzalintinib
Exelixis · Small molecule (oral, once daily)
FDA decision for metastatic colorectal cancer extended to March 3, 2027 after a major amendment (company-reported)
Major setbackIvonescimab
Summit Therapeutics · Bispecific antibody
FDA issued a Complete Response Letter on November 15, 2026: progression-free survival improved, but overall survival was not statistically significant
Why cancer drug development is different
Cancer drugs face a paradox. Oncology attracts more development than any other area, yet programs have historically been among the least likely to succeed, with only about 1 in 19 drugs entering Phase 1 reaching approval in the BIO analysis. Tumors are genetically diverse, they evolve resistance, and many promising early signals do not survive randomized trials.
At the same time, the regulatory path for serious cancers is well developed. Accelerated approval on response rates, Breakthrough Therapy designation, and priority review are all common, which helps explain why oncology applications that reach the FDA have usually been approved. See How Does the FDA Approve New Drugs?
The drugs we track
| Drug | Approach | Cancer | Status |
|---|---|---|---|
| Daraxonrasib (Rasonque) | Oral RAS(ON) inhibitor | Pancreatic | FDA-approved August 2026 |
| Vepdegestrant (Veppanu) | Oral PROTAC estrogen receptor degrader | ESR1-mutated breast | FDA-approved May 2026 |
| Sacituzumab tirumotecan | TROP2 antibody–drug conjugate | Endometrial (first filing) | Under priority review; decision by June 15, 2027 (company-reported) |
| Zanzalintinib | Oral multitargeted kinase inhibitor + atezolizumab | Colorectal | Under review; decision March 3, 2027 (company-reported) |
| Ivonescimab | PD-1 × VEGF bispecific antibody | EGFR-mutant lung | FDA Complete Response Letter, November 2026 |
Three lessons from this group
- Genetic drivers work when the drug truly hits them. Daraxonrasib targets the RAS mutations that drive most pancreatic cancers and roughly doubled median overall survival in its Phase 3 trial.
- Biomarkers define who benefits. Vepdegestrant's benefit was clear in patients with ESR1 mutations but not significant in the full trial population, so its approval is limited to that group and paired with a companion diagnostic. See What Is Precision Medicine?
- Overall survival is the decisive endpoint when it is primary. Ivonescimab's global HARMONi trial met its progression-free survival endpoint, but the FDA declined approval because overall survival, also a primary endpoint, was not statistically significant. Sacituzumab tirumotecan and daraxonrasib, by contrast, both showed overall survival gains.
Reading oncology trial results
Cancer trials report several kinds of results, which carry very different weight:
| Endpoint | What it measures | Strength |
|---|---|---|
| Objective response rate | Share of tumors that shrink | Early signal; often from single-arm trials |
| Progression-free survival | Time until the cancer grows or the patient dies | A surrogate; faster to measure |
| Overall survival | Time until death from any cause | The most important outcome; hardest to show |
Company pipelines
- Merck & Co. · NYSE: MRK
Sources
- U.S. Food and Drug Administration. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma (August 26, 2026).Regulator
- U.S. Food and Drug Administration. FDA approves vepdegestrant for ESR1-mutated advanced or metastatic breast cancer (May 1, 2026).Regulator
- Summit Therapeutics. Form 8-K exhibit: update regarding ivonescimab Biologics License Application (November 15, 2026).Company-reported
- U.S. Food and Drug Administration. Guidance: Expedited Programs for Serious Conditions: Drugs and Biologics (2014).Regulator
- BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report
- ClinicalTrials.gov: active industry trials in this areaRegistry
For education and research only. Not medical advice and not investment advice. See our disclaimer.